Background
Dementia is an age-related clinical syndrome that devastates cognitive abilities and interferes in elderly people's daily activities. Although its incidence is decreasing due to improvements to public health systems and control of cardiovascular risk factors [1] , its prevalence is steadily increasing due to rising life expectancy of human populations [2] .
Dementia is linked to many underlying pathologies, with Alzheimer's disease (AD) being the most common condition. Clinical AD is a heterogeneous syndrome. Brain autopsies have shown that roughly 80% of clinical AD patients present with brain vascular pathology [3] in addition to the common neuropathological AD hallmarks: amyloidosis, neurofibrillary tangles, and cerebral amyloid angiopathy (CAA) [4] . In fact, brain vascular pathology has been shown to be an important risk factor for AD that accelerates cognitive decline [5] and lowers the threshold for clinical diagnosis of AD [6] . In that context, it has been suggested that dementia is represented by a gradient of neurodegenerative and vascular components [7] , from pure AD forms, with a strong neurodegenerative component, to pure vascular dementia (VaD) cases and in-between mixed pathologies, representing the coexistence of both neurodegenerative and vascular components [7] . Despite that, whether there are differential biological routes operating under different levels of vascular burden in clinical AD patients remains mostly unknown.
In the search for the etiology of AD, genetic factors play a pivotal role. Two forms of the disease can be differentiated according to individual genetic background. The Mendelian form is an uncommon disorder that mainly affects families with early-onset AD (,65 years), whereas the polygenic form is a complex disorder mainly appearing in sporadic cases with late-onset AD (LOAD) (.65 years). Highly penetrant mutations detected in families with early-onset AD have been pinpointed to three genes: APP [8] , PSEN1 [9] , and PSEN2 [10] , leading to the establishment of the amyloid hypothesis as a potential causal mechanism for the disease [11] .
LOAD heritability falls in the range of 13%-80% [12, 13] . Although APOE ε4 was the first to be discovered and still remains the strongest genetic risk factor for AD [14] , almost 40 additional genetic variants have been identified [15] [16] [17] using genome-wide association studies (GWAS) and large sequencing projects. Among the biological pathways underlying genetic hits, the roles of the immune system, cholesterol, amyloid, and tau metabolism have been highlighted [18] . Despite these, current genetic findings account for 31% of LOAD heritability [19] , and the biological picture of AD is still poorly understood. Several reasons can explain this. Among them, the presence of clinical and neuropathological heterogeneity between AD cases in genetic studies, as recently demonstrated [12] , might compromise the power to detect genuine genetic associations and decrease the estimates of risk attributed to genetic variation.
The neuropathological variability in clinical AD cases comprises a wide spectrum, from those with concomitant vascular brain disease to those with a pure AD phenotype, as previously proposed by Viswanathan et al. [7] . This large heterogeneity might hamper the identification of functional categories of genes underlying differential biological routes to dementia and might impact AD genetic studies. To gain insight into the causality networks behind AD clinical subgroups and to explore their impact in large GWAS, we conducted the Genome Research at Fundacio ACE (GR@ACE) study. This is a GWAS of dementia and its clinical endophenotypes defined based on AD's clinical certainty and the burden of vascular comorbidity. The GR@ACE is a unique genomic resource comprising the largest number of dementia cases diagnosed in a single memory clinic to date. First, we determined whether we could identify categories of known LOAD genes linked to clinical subgroups of AD cases. Next, we explored whether these categories suggested different biological routes. Finally, to assess the impact of these clinical subgroups of AD cases in GWAS findings, we metaanalyzed the GR@ACE data with independent GWAS series.
Methods

Subjects
GR@ACE cohort and phenotype definitions
The GR@ACE study comprises 4120 AD cases and 3289 control individuals (Table 1) . Cases were recruited from Fundaci o ACE, Institut Catal a de Neuroci encies Aplicades (Catalonia, Spain). Diagnoses were established by a multidisciplinary working group, including neurologists, neuropsychologists, and social workers, according to the Diagnostic and Statistical Manual of Mental Disorders-IV criteria for dementia and to the National Institute on Aging and Alzheimer's Association's (NIA-AA) 2011 guidelines for defining AD [20] (see Supplementary Material). In the present study, we considered AD cases as dementia individuals diagnosed with probable or possible AD at any moment of their clinical course.
We took advantage of this wide clinical definition to refine AD cases. Considering the dementia spectrum proposed by Viswanathan et al. [7] , we classified Gr@ACE AD patients according to the degree of clinical certainty for AD phenotype and the presence of vascular comorbidity, from "pure" clinical AD cases to mixed and vascular enriched cases. This approach was feasible due to Fundaci o ACE's endorsement of a primary and a secondary etiologic diagnosis as well as routine follow-up evaluations [21] (Supplementary Methods). Using the entire clinical chart of each subject, we differentiated five clinical subgroups of patients representing the GR@ACE endophenotypes: (1) the AD 111 endophenotype comprises individuals with a last clinical diagnosis of probable AD in both primary and secondary diagnoses (n 5 1854); (2) the AD 11 includes individuals diagnosed with probable AD in the primary diagnosis and probable or possible AD in the secondary diagnosis (n 5 2611); (3) the AD 1 encompasses patients diagnosed with probable or possible AD either in the primary diagnosis or in the secondary diagnosis (n 5 3797); (4) We removed samples with genotype call rates ,97%, excess heterozygosity, duplicates, samples genetically related to other individuals in the cohort, or sample mix-up (PIHAT .0.1875). If a sex discrepancy was detected, the sample was removed unless the discrepancy was safely resolved. To detect population outliers of non-European ancestry (.6 SD from European population mean), principal component analysis was conducted using SMARTPCA from EIGENSOFT 6.1.4 ( Fig. 1 A model including the top four PCs as covariates was used for the discovery stage because it exhibited the lowest inflation and optimal power compared with alternative tested models ( Supplementary Fig. 2 ). Further description is provided in Supplementary Methods. Power analysis was performed using QUANTO software v1.2.4 [23] to model the impact on statistical power at different MAFs and effect sizes in available case-control cohorts. Results were depicted using the ggplot2 package in R. Analyses were performed for a GWAS experiment that would meet criteria for genome-wide significance (P , 5 ! 10 28 ) and for a replication experiment that would meet P , .05 ( Supplementary Fig. 3 ). Calculations were performed considering a disease prevalence of 1.73%, according to registers in the Spanish population. GR@ACE GWAS data have been deposited into the European Genome-phenome Archive (https://ega-archive.org), which is hosted by the European Bioinformatics Institute and the Center for Genomic Regulation, under the accession number EGAS00001003424.
Genetic exploration of GR@ACE clinical endophenotypes and enrichment analysis
With the objective to explore whether different biological routes operate under different levels of vascular burden in clinical AD patients, first, we classified GR@ACE dementia cases to cover the dementia spectrum previously proposed by Viswanathan et al. [7] (see Section 2. Supplementary Table 1 . Then, we explored whether previously identified LOAD variants were more strongly associated with a specific subgroup of AD patients. We quantified the strength of the association for each variant across endophenotypes, named henceforth global effect change. It was calculated as the absolute difference between variant OR for extreme endophenotypes ( Table 1 ). Finally, we assessed the biological pathways underlying each category. We incorporated data from gene coexpression for each specific gene category using the GeneFriends tool (http://genefriends.org/) and performed pathway analysis of top coexpressed genes using the overrepresentation enrichment method in WebGestalt (http:// www.webgestalt.org/option.php) (see Supplementary Methods). With the objective to further explore potential additional trends in category C, we performed a specific subanalysis in this category, widely described in Supplementary Methods. To validate previous gene classification, which strongly determines the pathway analysis results, we conducted a stringent subanalysis (see Supplementary Methods and Supplementary Fig. 4 ).
1). Second, we extracted the effect (odds ratio [OR]) for known LOAD genetic variants (MAF .1%). See included variants in
Meta-analysis: Data sets and association analysis
To explore the impact of the different clinical endophenotypes in GWAS findings, we combined the whole GR@ACE GWAS data set, which represents a dementia set of samples and its endophenotypes with (1) genotype-level data from nine additional GWAS series (N 5 13,826), available through dbGaP (https://www.ncbi.nlm.nih.gov/gap) that we processed by applying identical quality control and imputation procedures to those described for the GR@ACE cohort (Supplementary Table 2 ) and (2) aggregated summary statistics available from the International Genomics Alzheimer's Project (IGAP) (http://web.pasteur-lille.fr/en/ recherche/u744/igap/igap_download.php) [24] , including IGAP stages I (N final 5 61,571) and IGAP I and II (N final 5 81,455) (Supplementary Methods). Meta-analyses were conducted using the inverse variant method in METAL software (https://genome.sph.umich.edu/wiki/METAL). The linkage disequilibrium (LD) score calculations, clumping, and conditional analysis are described in Supplementary Methods.
Replication of genome-wide significant findings
We then explored genome-wide significant (GWS) signals in an independent cohort of Spanish ancestry (N 5 4959). We extracted variants of interest from GWAS data, which were genotyped and processed applying similar methods to those explained for the GR@ACE study (Section 2.3). Finally, meta-analysis including the discovery stage, named stage I, and the replica data set, stage II, was performed as previously described. Results were interpreted according to the American Statistical Association guidelines [25, 26] .
Biological interpretation of meta-GWAS signals
Gene expression quantitative trait locus (eQTL) analysis was conducted to link meta-GWAS top signals to genes. Markers with moderate-to-high LD (r 2 0.6) with the novel lead markers were identified using LDlink [27] for European population and were included in this analysis. We used brain (n 5 11) and whole-blood (n 5 1) tissues from the GTEx v7 repository (https://www.gtexportal.org/home) for mapping cis-eQTLs (Supplementary Table 3 ). As an extension of GTEx tissue eQTL mapping, we explored brain eQTLs for GWS genomic regions using additional databases available via Functional Mapping and Annotation of Genome-Wide Association Studies (FUMA) [28] . We also performed functional annotation for GWS markers, chromatin interaction, and gene-based analysis using similar criteria to those previously described by Jansen et al. [17] (see Supplementary Methods).
Results
GR@ACE genome-wide association study
After quality control and imputation, the GR@ACE study encompassed 7409 unrelated individuals from the Spanish population and 7.7 million variants (l GC 5 1.03). The APOE-rs429358 marker was the only one to have a GWS association (OR 5 2.27 [2.06-2.50]; P 5 1.25 ! 10 262 ) (Fig. 1) . Four additional LOAD variants displayed statistically significant evidence of replication (BIN1-rs6733839, MAPT-rs2732703, MS4A2-rs983392, and PICALM-rs10792832) and nine additional markers presented a consistent direction for the effect (Supplementary Table 1 ). MAPT marker association remains significant in APOE ε4 noncarriers, but the effect size was stable in both strata (Supplementary Table 4 
Genetic exploration of GR@ACE clinical endophenotypes and enrichment analysis
To explore whether clinical AD subgroups, representing GR@ACE endophenotypes, reflected variations in the underlying biological pathways driving dementia, we classified LOAD genetic variants into three categories. Category A comprised variants strongly related to the purest form of clinical AD (i.e., subjects with probable AD in primary and secondary diagnoses). The most prominent locus of this category was APOE-rs429358 (AD (Fig. 2) . Subanalysis for category C is shown in Supplementary Results and Supplementary Table 6 . Next, we explored biological pathways for each gene category. Note that the regulation of vasculature development and blood vessel morphogenesis were only detected for genes in category A, which is more closely related to pure AD (P 5 2.03 ! 10 27 , P 5 1.90 ! 10 26 , respectively) ( Table 3 ). Additional categories indicated immune system pathways (category B, P 5 2.07 ! 10 27 ; category C, P 5 5.77 ! 10 215 ) (Table 3) . Finally, with the aim of validating previous results, we conducted a subanalysis by classifying LOAD genetic variants with more stringent classification criteria (Supplementary Methods). Again, APOE, CR1, MEF2C, MS4A2, and PICALM loci were found in category A; SORL1 and CASS4 were in category B; and additional AD loci were in category C ( Supplementary  Fig. 4 ). Regulation of vasculature development was exclusively identified as the top pathway in category A (P 5 2.14 ! 10 27 ) when we restricted the analysis to include those loci coexpressing with at least 4 LOAD genes (Supplementary Table 7 ). Further replication in cohorts with available neuropathological data would be recommended.
Meta-analysis of GR@ACE study with other data sets
To assess the impact of sample composition in AD GWAS, and look for new AD loci, we first combined the GR@ACE data set with nine additional genomic databases that had genotypic level data available. Subtle genomic inflation was detected, mainly explained by polygenicity (l GC 5 1.10; LD score intercept 5 1.04). Five regions were associated with LOAD (Fig. 3) ; of these, four (APOE-rs429358, PICALM-rs10792832, MS4A2-rs983392, and BIN1-rs6733839) have been previously linked to AD (Supplementary Table 8 (Supplementary Fig. 7 ). Among the top suggestive signals, we detected HBEGF-rs4150233 (OR 5 0.92 [0.90-0.95]; P 5 5.10 ! 10 28 ) previously identified by a transethnic GWAS [29] .
Next, meta-analysis of the whole GR@ACE data set with IGAP I and II enabled the identification, for the first time, of NDUFAF6-rs10098778 as a GWS signal (OR 5 0.94 [0. 91- Fig. 8 ). It was previously reported as a genome-wide suggestive signal by IGAP [24] . Recently, SCIMP-rs113260531, which is in complete LD with our lead marker (r 2 5 1), was associated with AD [17] .
Replication of genome-wide significant findings
Finally, we tested for replication of the new signals in an independent sample of 4959 Spanish individuals. The CNTNAP2-rs117834366, detected in the GWAS of GR@ACE VaD 11 endophenotype, had a P value of 0.79 with a similar effect direction to that reported previously but strongly deflated in the entire replica sample (OR 5 1.09 [0.66-1.78]; P 5 .79) ( Table 3) . Analysis of the subspecific VaD phenotype in the replica (N 5 89) would be highly inaccurate.
In the exploration of meta-GWAS findings, we observed that the ANKDR31-rs4704171-C marker increased the risk of AD (OR 5 1.10 [0.98-1.25]; P 5 .09; power 5 33%). Although the expected effect is in line with previous data, the precision of the estimate in this replica differs, ranging from a 2% decrease (a small negative association) to a 25% increase. Of note, the result emerging from the meta-analysis of the replica with the discovery sample (n 5 26,194) is compatible with its potential role in dementia (OR 5 1.18 [1.11-1.24]; P 5 1.15 ! 10 28 ) (Table 3) . See forest plot in Supplementary Fig. 9 .
We observed a similar effect direction in the NDUFAF6-rs10098778 marker to that reported in the discovery stage, with interval estimates ranging from a risk decrease of 11% to a risk increase of 5% (OR 5 0.96 [0.89-1.05]; P 5 .40; power 5 16%). This signal had a P 5 2.32 ! 10 28 in the final meta-analysis, including the whole GR@ACE data set, the replica, and IGAP I and II (n 5 91,373) ( Supplementary Fig. 9 ).
SCIMP-rs7225151 showed a risk effect in the whole replica. Limits of the interval were consistent with a positive association (OR 5 1.14 [1.01-1.29]; P 5 .047; power 5 39%; n cases 5 1943). In the AD 111 endophenotype, the marker presented the same positive risk effect direction (OR 5 1.07 [0.88-1.30]), although had P 5 .49, which could be mainly explained by a reduction of the sample size (power 5 19%; n cases 5 584). Our results for both meta-analyses, the final meta-analysis of the whole GR@ACE data set (n 5 91,373) and the final meta-analysis of GR@ACE AD 111 endophenotype, (n 5 85,055) were compatible with a potential effect of this marker in AD (Table 3) . See forest plots in Supplementary Fig. 9 .
Biological interpretation of meta-GWAS signals
To identify candidate genes and potential causal variants within novel meta-GWAS regions, we conducted cis-eQTL mapping. The rs2335107 marker located in the ANKRD31 locus (chr5:74,451,693) was associated with the cortical expression of the long noncoding RNA (lncRNA) CTD-2235C13.3 (P 5 1.26 ! 10 25 ). This variant is located 83.4 kb from the meta-GWAS lead single nucleotide polymorphism (rs4704171, chr5:74,368,254), and both are in complete LD (r 2 5 1). The CTD-2235C13.3 gene is located 1.6 kb from the HMGCR locus, and its function is unknown. The NDUFAF6 region mapped for NDUFAF6 RNA cortical expression (P 5 5.56 ! 10 26 ) and for TP53INP1 RNA blood expression (P 5 1.17 ! 10 210 ). Finally, rs73976325 (chr17:5,123,227), located in the SCIMP locus, to 13.8 kb from the meta-GWAS top signal (rs7225151, chr17:5,137,047), mapped to brain cis-acting eQTL for AC012146.1 lincRNA (P 5 2.15 ! 10 27 ). Two additional markers were pinpointed to blood eQTLs, SCIMP-rs6502851 (P 5 3.89 ! 10 208 ) and RABEPrs59277121 (P 5 3.89 ! 10 28 ) (Supplementary Table 3 ). In an additional prioritization strategy, combining information from positional mapping, eQTL, chromatin interaction, and gene-based genome-wide association analysis via FUMA, results pointed to ANKDR31 and POLK for the ANKDR31 genomic region, as well as NDUFAF6 and TP53INP1 for the NDUFAF6 region (Supplementary Table 9 ). Further description is provided in Supplementary Information and Supplementary Table 9.
Discussion
We present a comprehensive GWAS of AD dementia cases. This represents the first pilot study exploring the genetics and underlying biological pathways of subgroups of patients with AD, defined based on vascular burden. We showed differential biological routes underlying clinical endophenotypes and demonstrated how these differential subgroups of patients with AD impact GWAS discoveries. The GR@ACE study represents a unique genomic resource because all affected cases were diagnosed in a single memory clinic using the same screening and diagnostic techniques. This might limit potential sources of clinical variation between study participants, recently demonstrated in a large meta-GWAS [12] . Based on the increase in evidence suggesting that vascular brain pathology can act concomitantly with AD to produce a more rapid cognitive decline [5] , we explored the effect of known LOAD loci across different levels of vascular burden in dementia patients using only clinical definitions. Our basic idea was to dissect, from a molecular point of view, the model previously proposed by Viswanathan et al. [7] . We observed three categories of loci, which might reflect the disease's clinical heterogeneity, from vascular and mixed forms to a "purer" AD phenotype. Intriguingly, we detected vascular processes to be the main causal mechanism in clinically pure AD and found the immune system pervasively detected across the three categories. Although both pathways have been previously associated with LOAD by network analysis [30] , this is the first study to show that the association with the vascular system is conducted by AD-specific clinical subgroup.
It should be noted that the present study used clinical criteria to define the AD cases [20] , but recently the classification of AD has evolved. In 2018, the NIA-AA proposed a novel research framework for the biological classification of AD based on the presence in vivo of biomarker evidences for amyloid (A), tau (T), and neurodegeneration (N), as surrogate of the neuropathological state of an individual [31] . The AT(N) biomarker system allows the classification of individuals into three categories: those with a normal biomarker profile, those with biomarkers compatible with AD change, and those with biomarkers compatible with non-AD pathological changes [31] . Using the NIA-AA approach, the generation of subgroups of AD patients considering vascular pathology would be unfeasible, as nowadays the ATN classification does not integrate measures of vascular dysfunction. Taking into account that most of dementia cases are caused by mixed pathologies, the current system seems deeply incomplete to study the probable interaction between neurodegeneration and vascular dysfunction. This idea has also been claimed by others [32, 33] . Thus, we encourage other groups to contrast the proposed loci classification, which was based on the GR@ACE clinical endophenotypes, but using wellpowered GWAS cohorts with available neuropathological data.
Silent changes occur in brain microvasculature during AD progression. In fact, CAA is a well-recognized AD pathological feature characterized by the accumulation of amyloid proteins in the walls of small cerebral vessels. CAA has been proposed to compromise the perivascular drainage of Ab from the brain to the peripheral system [34] . Almost all AD brains harbor CAA pathology to some extent, although in vivo most CAA cases remain undiagnosed, even using the validated Boston criteria [35] . Mendelian mutations of the APP gene have been found in CAA and AD [8, 36] . APOE ε4 and CR1 have been associated with an increased risk of CAA [37, 38] . In particular, distinct AD loci have been associated with capillary and noncapillary CAA [39] . Between them, APOE ε4 was strongly related to capillary CAA [39] . These links make it conceivable that a potential genetic overlap exists between CAA and AD and suggest that CAA pathology could represents an underlying process for AD. In that context, we think that intrinsic alterations to the vasculature could contribute to disease pathogenesis in more pure forms of AD, explaining our results. Conversely, in AD individuals with evident cerebrovascular lesions comprising mixed forms, the additional role of cardiovascular risk factors such as hypertension, atherosclerosis, or arteriosclerosis should be considered, as these could point to a systemic pathological state leading to vascular damage and dementia. This would agree with the limited genetic correlation between neurodegenerative and other neurologic disorders [12] , as well as with the results obtained from heterochronic parabionts in aging models [40] .
Understanding the role of vasculature pathology in AD seems to be a pertinent step. In that scenario, CAA would be a key AD hallmark. CAA represents the unique identified link between the vascular and amyloid hypotheses, but it has been completely neglected in the original hypothesis formulation.
From a clinical point of view, placing each patient somewhere along the disease spectrum proposed by Viswanathan et al. [7] is complex. A deep understanding of heterogeneity in AD seems necessary to design better genetic studies, which must drive the discovery of novel loci and, ultimately, innovative targets for AD therapies. In this study, we explored how clinical heterogeneity might impact GWAS findings by integrating distinct GWAS data sets with either the GR@ACE cohort as a whole or its endophenotypes. We found several new GWS signals that seem strongly dependent on the sample composition. For example, after combining IGAP stages I and II with the entire GR@ACE data set, we identified genetic signals in the NDUFAF6 genomic region but not in the SCIMP region. When this exercise was conducted using GR@ACE endophenotypes, the SCIMP signal was detected using the clinically "pure" AD GR@ACE endophenotype. It should be noted that the power to detect SCIMP signal in the meta-analysis with GRA@ACE dementia and GR@ACE AD 111 was 75 and 70%, respectively. We tried to replicate this finding in a purer AD data set without clinical mixed dementia cases, but the available number of clinical AD 111 cases might be compromising the statistical power to replicate (N cases 5 584; power 5 19%). Despite that, we think that using specific clinical subgroups of the AD population might empower genetic studies to detect genes associated with specific disease axes.
An alternative strategy is taking advantage of clinical heterogeneity. Specifically, heterogeneity might play a dual role in genetic studies. Although it might decrease the power to detect genes associated with more specific clinical subgroups, incorporating detailed clinical AD definitions can also promote identifying genes shared with other conditions or copathologies such as small vessel disease (SVD). In fact, this was the case for the ATP5H locus, which was previously found to be associated with AD [41] and more recently found in relation to SVD [42] . We think that the same could apply to the ANKRD31 finding. ANKRD31 encodes a protein containing ankyrin repeats, which is linked with neurodevelopmental disorders [43] . Of note, ANKRD31 GWAS signal mapped to the brain eQTL of a lncRNA, located 1.6 kb from the HMGCR locus and residing in the COL4A3BP gene. The HMGCR locus is one of the most important coregulators of cholesterol biosynthesis, and it is the therapeutic target of statins. The COL4A3BP gene is involved in lipid transport [44] . Several studies have linked HMGCR polymorphisms and AD risk or age at onset for AD [45] , and the cholesterol pathway has been identified to be a biological route shared between AD and SVD. Interestingly, markers in the POLK locus, associated by gene-based genome-wide association analysis on this study and located in the same disequilibrium block of ANKDR31 (Fig. 3) , jointly conferred risk for AD and plasma levels of LDL [46] . Considering prior findings, our results are consistent with this genomic region having a role in mixed dementia. The reported genetic signal should be considered a highly probable finding, although independent replications are still required.
In the present work, NDUFAF6 signals reached GWS for the first time. This finding presented the same effect direction in the independent sample (power 5 16%) and remains as GWS after the final meta-analysis. Our lead GWAS marker is in high LD with NDUFAF6-rs4735340, the top suggestive signal reported by Kunkle et al. [18] at this region (r 2 5 0.95, for Utah residents of European ancestry population). Despite that, there are subtle differences in LD estimates for the Iberian population (r 2 5 0.87), suggesting that the genetic architecture of the Spanish population could be helping to pinpoint the region of interest. This region is in the close vicinity of TP53INP1, previously associated with AD by a gene-based approach [47] . TP53INP1 is involved in mitochondrial function. Considering these findings and results emerging from eQTL analysis, it would be feasible that a regulatory element for NUDFAF6 resides upstream of the TP53INP1 locus. We also detected that the SCIMP signal was mainly conducted by a specific group of AD cases. This signal was reported to be a suggestive signal by IGAP [24] , and a proxy of it (SCIMP-rs113260531) reached GWS recently [17] . SCIMP regions has been involved in several eQTLs, from uncharacterized cortical lncRNA to blood eQTLs in SCIMP and RABEP1 loci, both associated with immune system function [48, 49] . The CD33 locus remains a controversial LOAD locus because large meta-GWAS were unable to replicate this signal [24] , but here it reached GWS. We previously proposed that cryptic population substructure could explain the divergent observations for this locus [50] .
Note that the lack of definitive neuropathological data for AD cases is a severe limitation of the present study. Clinical definitions have important uncertainties, and diagnosis misclassifications sometimes occur. Hence, some AD individuals included in enriched AD endophenotypes may present concomitant vascular brain disease. The generation of large histopathological GWAS cohorts with associated quantitative data on each pathological hallmark is the ultimate solution to tackling the intrinsic heterogeneity in AD. Unfortunately, there are few examples of neuropathological cohorts: only one GWAS has investigated the genetics of CAA, with APOE being the unique GWS signal [37] . In this study, a small number of AD cases evolved to vascular dementia during follow-up. Large cross-sectional clinical GWAS cannot control diagnostic changes occurring in clinical practice. Clinical diagnosis is a dynamic variable, so understanding the genetic profiles of subgroups of patients evolving to other pathologies would provide powerful information.
It should be considered that there is a limitation in reducing the sample size by splitting the cohort into different endodophenotypes, instead of combining them. Despite that, spanning the spectrum of dementia individuals to generate clinical endophenotypes provided us a versatile design, which let us explore the effect of heterogeneity in GWAS and replicate the main findings of pathway analysis using an alternative strategy. The limited number of VaD cases in subgroup analysis limits the accuracy of gene categorization and pathway analysis. Finally, the exact effector genes for LOAD genetic findings remain unclear. This is a severe limitation to pathway analysis that can only be circumvented by isolating the causative mutations. Independent replication will be needed to corroborate our new GWS signals. In that sense, the selection of specific patient groups might lead to successful replication studies.
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